サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784953

他家細胞療法の世界市場

Allogeneic Cell Therapy

出版日
ページ情報
英文 275 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
他家細胞療法の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 275 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

他家細胞療法の世界市場は2030年までに17億米ドルに達する見込み

2024年に4億2,660万米ドルと推定される他家細胞療法の世界市場は、2024～2030年の分析期間においてCAGR 25.4%で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである幹細胞治療は、CAGR29.8%を記録し、分析期間終了時には12億米ドルに達すると予測されます。非幹細胞治療分野の成長率は、分析期間のCAGRで18.3％と推定されます。

米国市場は1億1,620万米ドルと推定、中国はCAGR34.4％で成長予測

米国の他家細胞療法市場は、2024年に1億1,620万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR34.4%で推移し、2030年には4億2,150万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.9%と23.1%と予測されています。欧州では、ドイツがCAGR 21.5%で成長すると予測されています。

世界の他家細胞療法市場- 主要動向と促進要因のまとめ

他家細胞療法が再生医療で勢いを増す理由とは？

他家細胞療法は、再生医療の分野で急速に支持を集めています。その原動力は、既製のソリューションで幅広い慢性疾患や変性疾患を治療できる可能性にあります。患者自身の細胞に依存する自己細胞療法とは異なり、他家細胞療法は、すぐに使用できるように拡張・保存が可能なドナー由来の細胞を使用し、スケーラブルで費用対効果の高い治療オプションを提供します。このアプローチは、血液悪性腫瘍、自己免疫疾患、心血管疾患などの治療において特に有望視されています。慢性疾患の有病率の増加と革新的な治療法に対する需要の高まりは、ヘルスケア全体における同種療法の採用を加速させています。FDAやEMAなどの規制機関は、有望な同種療法の臨床試験や迅速承認を積極的に支援しており、市場の成長をさらに促進しています。さらに、凍結保存と細胞拡大技術の進歩により、同種細胞製品の利用可能性と効力が強化され、細胞の生存率と保存期間に関する主要課題に対処しています。効果的で容易に入手可能な細胞ベースの治療法に対する需要が高まり続ける中、他家細胞療法は現代医療のゲームチェンジャーとして台頭しつつあります。

技術の進歩は他家細胞療法市場をどのように牽引しているのでしょうか？

技術革新は、製造、保存、送達プロセスを改善することにより、他家細胞療法の進歩に極めて重要な役割を果たしています。CRISPR-Cas9遺伝子編集や人工多能性幹細胞（iPSC）技術のような細胞工学技術の画期的な開発により、有効性が強化され免疫拒絶反応のリスクが低減された既製の治療法の開発が可能になりました。自動化とバイオプロセス技術は、スケーラビリティとコスト効率を大幅に改善し、一貫した品質基準で同種細胞を大量に生産することを可能にしました。高度なバイオリアクター・システムは現在、細胞増殖を最適化するために使用されており、細胞の機能性を維持しながら高い収率を確保しています。さらに、AIを活用した解析や機械学習アルゴリズムが品質管理プロセスに組み込まれ、細胞の特性をモニターし、治療結果を予測するようになっています。3Dバイオプリンティング技術の採用も勢いを増しており、研究者は再生応用のために同種細胞を用いて複雑な組織構造を作成することができます。このような技術的進歩は、生産コストを削減するだけでなく、同種細胞治療の安全性と有効性を高め、広く臨床に採用される有力な選択肢となっています。

医療分野での他家細胞療法の応用範囲とは？

他家細胞療法の応用範囲は、腫瘍学や血液学といった従来の分野にとどまらず、整形外科、皮膚科学、神経学といった分野にも広がっています。整形外科領域では、同種間葉系幹細胞（MSC）が軟骨再生、骨癒合、変形性関節症の治療においてその可能性が広く検討されています。皮膚科領域では、創傷治癒、熱傷治療、美容への応用が他家細胞療法に掲げられており、皮膚再生における臨床研究が有望な結果を示しています。神経学もまた新たなフロンティアであり、パーキンソン病、アルツハイマー病、脊髄損傷などの神経変性疾患に対する同種幹細胞の利用研究が進行中です。さらに、心血管系分野では、組織修復や血管新生を促進することで、心不全や末梢動脈疾患の治療に対する他家細胞療法への関心が高まっています。免疫療法や生体材料などの既存治療と組み合わせた同種療法の採用が増加しており、臨床応用がさらに拡大し、複数の治療領域で市場の需要を牽引しています。

他家細胞療法市場の成長を促進する主な要因は？

世界の他家細胞療法市場の成長は、細胞製造技術の進歩、再生医療への投資の増加、慢性疾患の罹患率の上昇など、いくつかの要因によって牽引されています。既製の治療ソリューションへのシフトは、特に即時介入が重要な腫瘍学や自己免疫疾患管理において同種療法の採用を加速させています。革新的な細胞ベースの製品に対する規制当局の支援は、有利な償還政策の確立とともに、市場拡大に重要な役割を果たしています。患者やヘルスケア提供者の間で低侵襲治療オプションに対する需要が高まっていることも、様々な医療専門分野での他家細胞療法の採用をさらに後押ししています。さらに、臨床試験の増加やバイオ医薬品企業と研究機関との提携が、新たな同種細胞製品の技術革新と商業化を促進しています。細胞治療における研究開発イニシアチブを支援するための公的・民間セクターからの資金提供の増加は、同種細胞治療の世界の普及と手頃な価格への道を開き、市場成長をさらに促進すると予想されます。

セグメント

治療タイプ（幹細胞療法、非幹細胞療法）;治療領域（血液疾患、皮膚疾患、その他の治療領域）

調査対象企業の例

  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics
  • Atara Biotherapeutics, Inc.
  • Biosolution Co., Ltd.
  • Gilead Sciences, Inc（Kite）
  • IOVANCE Biotherapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals Plc
  • Medipost Co., Ltd.
  • Nkarta Therapeutics
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29093

Global Allogeneic Cell Therapy Market to Reach US$1.7 Billion by 2030

The global market for Allogeneic Cell Therapy estimated at US$426.6 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 25.4% over the analysis period 2024-2030. Stem Cell Therapies, one of the segments analyzed in the report, is expected to record a 29.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Non-stem Cell Therapies segment is estimated at 18.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$116.2 Million While China is Forecast to Grow at 34.4% CAGR

The Allogeneic Cell Therapy market in the U.S. is estimated at US$116.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$421.5 Million by the year 2030 trailing a CAGR of 34.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.9% and 23.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.5% CAGR.

Global Allogeneic Cell Therapy Market - Key Trends & Drivers Summarized

Why Is Allogeneic Cell Therapy Gaining Momentum in Regenerative Medicine?

Allogeneic cell therapy is rapidly gaining traction in the field of regenerative medicine, driven by its potential to treat a wide range of chronic and degenerative diseases with off-the-shelf solutions. Unlike autologous cell therapies, which rely on a patient's own cells, allogeneic cell therapy uses donor-derived cells that can be expanded and stored for immediate use, offering a scalable and cost-effective treatment option. This approach has been particularly promising in the treatment of conditions such as hematological malignancies, autoimmune disorders, and cardiovascular diseases. The increasing prevalence of chronic illnesses, coupled with the growing demand for innovative treatment modalities, has accelerated the adoption of allogeneic therapies across the healthcare landscape. Regulatory agencies such as the FDA and EMA are actively supporting clinical trials and fast-track approvals for promising allogeneic therapies, further fueling market growth. Additionally, advancements in cryopreservation and cell expansion techniques are enhancing the availability and potency of allogeneic cell products, addressing key challenges related to cell viability and shelf life. As the demand for effective and readily available cell-based therapies continues to rise, allogeneic cell therapy is emerging as a game-changer in modern medicine.

How Are Technological Advancements Driving the Allogeneic Cell Therapy Market?

Technological innovations are playing a pivotal role in advancing allogeneic cell therapy by improving the manufacturing, storage, and delivery processes. Breakthroughs in cell engineering techniques, such as CRISPR-Cas9 gene editing and induced pluripotent stem cell (iPSC) technology, have enabled the development of off-the-shelf therapies with enhanced efficacy and reduced immune rejection risks. Automation and bioprocessing technologies have significantly improved scalability and cost-efficiency, making it possible to produce large batches of allogeneic cells with consistent quality standards. Advanced bioreactor systems are now being used to optimize cell expansion, ensuring high yields while maintaining cellular functionality. In addition, AI-powered analytics and machine learning algorithms are being integrated into quality control processes to monitor cell characteristics and predict therapeutic outcomes. The adoption of 3D bioprinting techniques is also gaining momentum, allowing researchers to create complex tissue structures using allogeneic cells for regenerative applications. These technological strides are not only reducing production costs but also enhancing the safety and efficacy of allogeneic cell therapies, making them a viable option for widespread clinical adoption.

What Are the Expanding Applications of Allogeneic Cell Therapy Across Medical Specialties?

The application scope of allogeneic cell therapy is expanding beyond traditional areas such as oncology and hematology, reaching into fields such as orthopedics, dermatology, and neurology. In orthopedic medicine, allogeneic mesenchymal stem cells (MSCs) are being widely explored for their potential in cartilage regeneration, bone healing, and the treatment of osteoarthritis. The dermatology sector is leveraging allogeneic cell therapy for wound healing, burn treatment, and aesthetic applications, with clinical studies demonstrating promising outcomes in skin regeneration. Neurology is another emerging frontier, with ongoing research into the use of allogeneic stem cells for neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease, and spinal cord injuries. Additionally, the cardiovascular segment is experiencing increased interest in allogeneic cell therapy for treating heart failure and peripheral artery diseases by promoting tissue repair and angiogenesis. The rising adoption of allogeneic therapies in combination with existing treatments, such as immunotherapies and biomaterials, is further expanding their clinical applications and driving market demand across multiple therapeutic areas.

What Are the Key Factors Driving the Growth of the Allogeneic Cell Therapy Market?

The growth in the global allogeneic cell therapy market is driven by several factors, including advancements in cell manufacturing technologies, increasing investment in regenerative medicine, and the rising incidence of chronic diseases. The shift towards off-the-shelf treatment solutions is accelerating the adoption of allogeneic therapies, particularly in oncology and autoimmune disease management, where immediate intervention is critical. Regulatory support for innovative cell-based products, along with the establishment of favorable reimbursement policies, is also playing a crucial role in market expansion. The rising demand for minimally invasive treatment options among patients and healthcare providers is further propelling the adoption of allogeneic cell therapies across various medical specialties. Furthermore, the growing number of clinical trials and partnerships between biopharmaceutical companies and research institutions are driving innovation and the commercialization of new allogeneic products. The increasing availability of funding from public and private sectors to support R&D initiatives in cell therapy is expected to further fuel market growth, paving the way for wider accessibility and affordability of allogeneic therapies globally.

SCOPE OF STUDY:

The report analyzes the Allogeneic Cell Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Stem Cell Therapies, Non-stem Cell Therapies); Therapeutic Area (Hematological Disorders, Dermatological Disorders, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics
  • Atara Biotherapeutics, Inc.
  • Biosolution Co., Ltd.
  • Gilead Sciences, Inc (Kite)
  • IOVANCE Biotherapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals Plc
  • Medipost Co., Ltd.
  • Nkarta Therapeutics
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Allogeneic Cell Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Investments in Regenerative Medicine and Advanced Therapies Propel Growth of the Allogeneic Cell Therapy Market
    • Increasing Prevalence of Chronic Diseases and Degenerative Disorders Expands Addressable Market for Allogeneic Stem Cell Therapies
    • Growing Adoption of Off-the-Shelf Cell Therapies Strengthens the Business Case for Allogeneic Cell-Based Treatments Over Autologous Therapies
    • Advancements in CRISPR and Gene-Editing Technologies Drive Innovation in Genetically Modified Allogeneic Cell Therapies
    • Regulatory Approvals and Accelerated Pathways for Advanced Cell Therapies Expedite Market Entry of Novel Allogeneic Treatments
    • Emerging Role of Allogeneic Cell Therapies in Oncology Expands Market Opportunities for Immune Cell-Based Cancer Treatments
    • Surging Interest in Allogeneic Mesenchymal Stem Cell (MSC) Therapies Strengthens Market Growth in Autoimmune and Inflammatory Disease Treatments
    • Technological Innovations in Cell Manufacturing and Expansion Enhance Scalability and Cost-Effectiveness of Allogeneic Therapies
    • Growing Adoption of Allogeneic Induced Pluripotent Stem Cell (iPSC) Therapies Fuels Market Expansion in Neurological and Cardiovascular Applications
    • Rising Prevalence of Graft-Versus-Host Disease (GVHD) Drives Research into More Tolerogenic and Immuno-Compatible Allogeneic Therapies
    • Evolving Reimbursement Policies and Government Support for Regenerative Medicine Strengthen Market Adoption of Allogeneic Cell Therapies
    • Expanding Biobanking and Cell Repository Infrastructure Enhances Availability and Standardization of Allogeneic Cell Therapy Products
    • Growing Demand for Universal Donor Cell Lines Expands the Market Potential for Genetically Engineered Allogeneic Therapies
    • Advancements in 3D Bioprinting and Tissue Engineering Open New Frontiers for Allogeneic Cell-Based Tissue Regeneration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Allogeneic Cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Allogeneic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Allogeneic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Stem Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Stem Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Stem Cell Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-stem Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-stem Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-stem Cell Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hematological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Dermatological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Dermatological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Dermatological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • JAPAN
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CHINA
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • EUROPE
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Allogeneic Cell Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Allogeneic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • FRANCE
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • GERMANY
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Allogeneic Cell Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Allogeneic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • INDIA
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Allogeneic Cell Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Allogeneic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Allogeneic Cell Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Allogeneic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AFRICA
    • Allogeneic Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Allogeneic Cell Therapy by Therapy Type - Stem Cell Therapies and Non-stem Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Allogeneic Cell Therapy by Therapy Type - Percentage Breakdown of Value Sales for Stem Cell Therapies and Non-stem Cell Therapies for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Allogeneic Cell Therapy by Therapeutic Area - Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Allogeneic Cell Therapy by Therapeutic Area - Percentage Breakdown of Value Sales for Hematological Disorders, Dermatological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION